Visipaque 320

  • Imaging agents

Visipaque 320 Generic Name & Formulations

General Description

Iodixanol 652mg/mL; soln for inj; contains sodium 1.11mg/mL, organically bound iodine 320mg/mL; preservative-free.

Pharmacological Class

Radiographic contrast medium.

See Also

How Supplied

Bottles (50mL, 100mL, 150mL, 200mL)—10


Generic Availability


Visipaque 320 Indications


Intra-arterial: Digital subtraction angiography, angiocardiography (left ventriculography and selective coronary arteriography), peripheral arteriography, visceral arteriography, and cerebral arteriography. IV: CT imaging of the head and body, excretory urography, and coronary computed tomography angiography (CCTA) to assist in the diagnostic evaluation of suspected coronary artery disease.

Visipaque 320 Dosage and Administration


≥12yrs: Usual single doses: Intra-arterial (digital subtraction angiography): Carotid or vertebral arteries: 5–8mL (max 175mL); Aortography: 10–50mL; Major branches of aorta: 2–10mL; Aortofemoral runoffs: 6–15mL; Peripheral arteries: 3–15mL (max 250mL). Intra-arterial (arteriography): Carotid arteries: 10–14mL; Vertebral arteries: 10–12mL (max 175mL); Right coronary artery: 3–8mL; Left coronary artery: 3–10mL; Left ventricle: 20–45mL (max 200mL); Renal arteries: 8–18mL; Aortography: 30–70mL; Major branches of aorta: 10–70mL; Aortofemoral runoffs: 20–90mL; Peripheral arteries: 15–30mL (max 250mL). IV: CT of head or body: 75–150mL or 100–150mL bolus infusion; max 150mL. Excretory urography (normal renal function): 1mL/kg; max 100mL. CCTA (bolus inj with test bolus or bolus tracking): 50–150mL (4–7mL/sec); max 150mL.


<12yrs: Intra-arterial for angiocardiography, cerebral arteriography, and visceral arteriography: 1–2mL/kg; max 4mL/kg.

Visipaque 320 Contraindications


Intrathecal use.

Visipaque 320 Boxed Warnings

Boxed Warning

Not for intrathecal use.

Visipaque 320 Warnings/Precautions


Have resuscitation equipment and trained personnel available. Homocystinuria: avoid. Severe renal impairment. Cardiovascular disease. CHF. Diabetes. Advanced vascular disease. Multiple myeloma/paraproteinaceous diseases. Pheochromocytoma. Catecholamine-secreting paragangliomas. Thyroid dysfunction (esp. children 0–3yrs); monitor. Homozygous sickle cell disease. History of severe cutaneous adverse reactions: avoid. Maintain adequate hydration. Avoid extravasation. Children: asthma, cyanotic and acyanotic heart disease, CHF, serum creatinine >1.5mg/dL, immature renal function, dehydration: increased risk of adverse effects. Elderly. Pregnancy. Nursing mothers: not recommended.

Visipaque 320 Pharmacokinetics

See Literature

Visipaque 320 Interactions


May increase risk of metformin-induced lactic acidosis. Recently received cholecystographic agents in patients with hepatic or biliary disorder; increased risk of renal toxicity. Do not mix with other drugs. Caution with concomitant beta-blockers. Do not use laxatives, diuretics, or preparatory dehydration prior to administration. Radioactive iodine uptake studies may not accurately reflect thyroid function for at least 16 days.

Visipaque 320 Adverse Reactions

Adverse Reactions

Rash, erythema, pruritus, scotoma; acute kidney injury, thromboembolic events, hypersensitivity reactions, others.

Visipaque 320 Clinical Trials

See Literature

Visipaque 320 Note

Not Applicable

Visipaque 320 Patient Counseling

See Literature